What's breaking now, across thousands of outlets.
The latest installment in BioPharma Dive’s data visualization series features a closer look at Kodiak’s stock performance and Hengrui's ties with U.S. and European drugmakers.
We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.
The next era of primary care will require intelligence that moves directly into the workflow, writes Sentara Health's head of ambulatory care.
'I can't go through World FTD Awareness Week without talking about Bruce. He is the driving force behind my advocacy,' Emma Heming Willis wrote.
Plus news about Regeneron. Summit Therapeutics to test cancer drug with Datroway: The biotech agreed to partner with AstraZeneca and Daiichi Sankyo on a clinical trial collaboration, testing its…
While the transition to motherhood can be challenging for anyone, barriers such as inadequate health literacy, unreliable transportation, difficulty navigating a complex health care system, limited access to child care or insecure housing can be the tipping point between a new mom accessing needed care or going without it.
Researchers at the Cancer Epigenetics Institute (CEI) at Fox Chase Cancer Center have discovered how to control and stop the amplification of MYC—one of the most commonly altered cancer genes linked to aggressive tumor growth and treatment resistance.
One in 100 adolescents and young adults in the United States has an opioid use disorder (OUD) and, with the rise of fentanyl in the drug supply, overdoses in this age group have risen sharply since 2019.
